Namiki Izumi focuses on Internal medicine, Hepatocellular carcinoma, Gastroenterology, Virology and Hepatitis C virus. His Internal medicine research is multidisciplinary, incorporating perspectives in Ribavirin, Surgery and Immunology. The study incorporates disciplines such as Carcinoma and Hazard ratio in addition to Hepatocellular carcinoma.
His studies in Gastroenterology integrate themes in fields like Stage, Adverse effect and Cohort study. His work in Virology tackles topics such as Genotype which are related to areas like Fulminant hepatitis and Acute hepatitis B. Namiki Izumi works mostly in the field of Interferon, limiting it down to concerns involving NS5A and, occasionally, Peptide sequence.
Namiki Izumi mainly investigates Internal medicine, Gastroenterology, Hepatocellular carcinoma, Virology and Hepatitis C virus. His work carried out in the field of Internal medicine brings together such families of science as Ribavirin and Oncology. His Ribavirin research includes elements of Interferon and Combination therapy.
His work focuses on many connections between Gastroenterology and other disciplines, such as Adverse effect, that overlap with his field of interest in Placebo. His Hepatocellular carcinoma research includes themes of Carcinoma, Surgery and Hazard ratio. His Hepatitis C virus study is concerned with the larger field of Immunology.
Internal medicine, Hepatocellular carcinoma, Gastroenterology, In patient and Oncology are his primary areas of study. His is doing research in Hazard ratio, Adverse effect, Confidence interval, Hepatology and Clinical trial, both of which are found in Internal medicine. Namiki Izumi works mostly in the field of Hepatology, limiting it down to topics relating to Hepatitis C virus and, in certain cases, Hemodialysis, as a part of the same area of interest.
His Hepatocellular carcinoma study incorporates themes from Liver function and Cohort. Namiki Izumi interconnects Fibrosis and Incidence in the investigation of issues within Gastroenterology. Namiki Izumi has included themes like Hepatitis B and Hepatitis C in his Cirrhosis study.
His primary scientific interests are in Internal medicine, Hepatocellular carcinoma, Gastroenterology, Adverse effect and Lenvatinib. His work in Internal medicine is not limited to one particular discipline; it also encompasses Hepatectomy. His Hepatocellular carcinoma research is multidisciplinary, incorporating elements of Carcinoma, Oncology, Cohort and Hazard ratio.
Namiki Izumi focuses mostly in the field of Gastroenterology, narrowing it down to topics relating to Receiver operating characteristic and, in certain cases, Mac 2 binding protein and Subgroup analysis. His Adverse effect study integrates concerns from other disciplines, such as Hepatitis C virus, Platelet, Platelet transfusion, Chronic liver disease and Placebo. His research integrates issues of Ribavirin, DIRECT ACTING ANTIVIRALS, Sustained Virologic Responses, Sofosbuvir and Anemia in his study of Hepatitis C.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Yasuhito Tanaka;Nao Nishida;Masaya Sugiyama;Masayuki Kurosaki.
Nature Genetics (2009)
Mutations in the Nonstructural Protein 5a Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus 1b Infection
Nobuyuki Enomoto;Ikuo Sakuma;Yasuhiro Asahina;Masayuki Kurosaki.
The New England Journal of Medicine (1996)
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.
N Enomoto;I Sakuma;Y Asahina;M Kurosaki.
Journal of Clinical Investigation (1995)
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
Masatoshi Kudo;Namiki Izumi;Norihiro Kokudo;Osamu Matsui.
Digestive Diseases (2011)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada;Yoshiyuki Suzuki;Kenji Ikeda;Joji Toyota.
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Masashi Mizokami;Osamu Yokosuka;Tetsuo Takehara;Naoya Sakamoto.
Lancet Infectious Diseases (2015)
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo;Osamu Matsui;Namiki Izumi;Hiroko Iijima.
Liver cancer (2014)
Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines)
Norihiro Kokudo;Kiyoshi Hasegawa;Masaaki Akahane;Hiroshi Igaki.
Hepatology Research (2015)
Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
Takumi Kawaguchi;Namiki Izumi;Michael R. Charlton;Michio Sata.
Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey
Kiyoshi Hasegawa;Norihiro Kokudo;Masatoshi Makuuchi;Namiki Izumi.
Journal of Hepatology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: